

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Romvimza Prior Authorization Policy

- Romvimza™ (vimseltinib capsules – Deciphera/Ono Pharma)

REVIEW DATE: 02/19/2025

OVERVIEW

Romvimza, a kinase inhibitor, is indicated for the treatment of symptomatic **tenosynovial giant cell tumor** (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity in adults.¹

Guidelines

National Comprehensive Cancer Network (NCCN) soft tissue sarcoma guidelines (version 5.2024 – March 10, 2025) recommend Romvimza or Turalio as a “preferred regimens” for the treatment of tenosynovial giant cell tumor/ pigmented villonodular synovitis (both category 1).² Other medications listed as “useful in certain circumstances” include imatinib and nilotinib (both category 2A).

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Romvimza. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Romvimza is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).** Approve for 1 year if the patient meets BOTH of the following (A and B):
 - A) Patient is ≥ 18 years of age; AND
 - B) The tumor is not amenable to improvement with surgery.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Romvimza is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Romvimza® capsules [prescribing information]. Waltham, MA: Deciphera; February 2025.
 2. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (version 5.2024 – March 10, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed April 9, 2025.
-

HISTORY

Type of Revision	Summary of Changes	Review Date
New policy	--	02/19/2025
Update	04/09/2025: The overview section was updated with guideline recommendations from National Comprehensive Cancer Network.	--